SubHero Banner

Xolair® (omalizumab) – Expanded indication

July 6, 2016 – The FDA approved Genentech’s Xolair (omalizumab) for use in patients 6 years of age and older with moderate to severe asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

Download PDF